Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation
Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation
Active, not recruiting · NCT06990529 · Registry updated 2026-09-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation | PIDs Linked to PI3K | Active, not recruiting | Phase 2 | 2026-09-16 | NCT06990529 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Aixial Group | 3 |
| Pharming Technologies B.V. | 6 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| IIS La Fe | Valencia | Spain | 1 |
| Lahey Hospital & Medical Center | Burlington | United States | 26 |
| Mount Sinai Hospital | New York | United States | 225 |
| National Institute Of Health | Bethesda | United States | 7 |
| St James Hospital | Leeds | United Kingdom | 2 |